VassoloR.S.AnandJ.FoltaT.B. (2004) ‘Nonadditivity in portfolios of exploration activities: A real options based analysis of equity alliances in biotechnology’, Strategic Management Journal25, 1045–1061.
2.
VachaniS.SmithN.C. (2004) ‘Socially responsible pricing: Lessons from the pricing of aids drugs in developing countries’, California Management Review47(1), 117–145.
3.
RichardsonL.LuchsingerV. (2004) ‘International pharmaceuticals industry: The new marketing paradigm in the United States and unresolved issues of public policy’, Journal of American Academy of Business5(1/2):21–26.
4.
NarayananS.DesirajuR.ChintaguntaP. (2004) ‘Return on investment implications for pharmaceutical promotional expenditures: The role of marketing-mix interactions’, Journal of Marketing68(4), 90–106.
5.
WoodK.AngusD.C. (2004) ‘Pharmacoeconomic implications of new therapies in sepsis’, PharmacoEconomics22(14), 895–907.
6.
WardK.R.McDonaldM.H.B.SmithB.D. (2004) ‘Marketing due diligence: Translating marketing strategies into shareholder value’, Eclectic Autumn, 16–20.
